Stock Analysis, Dividends, Split History

XL / XL Group Ltd. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)14,590.82
Enterprise Value ($M)16,491.52
Book Value ($M)9,660.01
Book Value / Share37.33
Price / Book1.51
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 256,915,044
Common Stock Shares Outstanding 256,034,000
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.04
Return on Assets (ROA)-0.01
Return on Equity (ROE)-0.04
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Net Income-490.14
Earnings Per Share Diluted-2.16
Earnings Per Share Basic-2.16
Cash Flow Statement (mra) ($M)
Cash From Operations33.32
Cash from Investing662.73
Cash from Financing33.32
Identifiers and Descriptors
Central Index Key (CIK)875159
Related CUSIPS
G98290952 SB5LRLL23 G98294904 G98290OLD G98294954 B5LRLL200 0G9829010 G98294104 G98290902

Split History

Stock splits are used by XL Group Ltd. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Everest Re Dented, But Not Permanently Damaged

12h seekingalpha
With a significant revision to 2017 catastrophe losses, Everest Re's risk management skill looks more "average" than in prior events. (3-0)

AXA (AXAHF) CEO Thomas Buberl on Q2 2018 Results - Earnings Call Transcript

2018-08-06 seekingalpha
Okay, well good afternoon everyone and welcome to Axis 2018 Half Year Results. A very warm literally welcome to those in the room, welcome to those on the telephone, welcome to those on the webcast and again very warm welcome to those here in London. (1-0)

AXA: Moving Towards A P&C, Protection And Health Insurance Behemoth

2018-08-03 seekingalpha
On the 2nd of August, AXA reported its results for the first half of 2018. The year-to-date post-tax profit declined by 14% because of adverse non-recurring effects. (1-0)

XL Group (XL) Q2 Earnings Miss Estimates, Revenues Beat

2018-08-01 zacks
XL Group Ltd (XL - Free Report) reported second-quarter 2018 operating net income of 84 cents per share, which missed the Zacks Consensus Estimate by 6.7%. Moreover, the bottom line declined 12.5% from the prior-year quarter. Higher level of non-catastrophe loss, increase in expenses along with prior-year development from short tail lines in Insurance, were mainly responsible for the downside. (3-0)

What’s in the Cards for MetLife (MET) Stock in Q2 Earnings?

2018-07-30 investorplace
MetLife’s (NYSE:MET) second-quarter 2018 earnings release scheduled on Aug 1 is expected to showcase revenue growth on the back of sales growth in Asia and EMEA, growth in operating premiums plus fees and other revenues in its Group Benefits segment. (3-0)

Silicon Investor Message Boards

This table lists all message boards related to XL / XL Group Ltd. on message board site Silicon Investor.

Broadband Wireless Access [WCII, NXLK, WCOM, satellite..] Broadband Wireless Access [WCII, NXLK, WCOM, satellite..] Broadband Wireless Access [WCII, NXLK, WCOM, satellite..] Xilinx (XLNX) Xilinx (XLNX) Xilinx (XLNX)
Technology Select Stock .. Symbol : u0026#034; XLK u0026#034 Technology Select Stock .. Symbol : u0026#034; XLK u0026#034 Technology Select Stock .. Symbol : u0026#034; XLK u0026#034 Bill Wexleru0027s Trading Cabana Bill Wexleru0027s Trading Cabana Bill Wexleru0027s Trading Cabana
Pixelworks, Inc. (PXLW) Pixelworks, Inc. (PXLW) Pixelworks, Inc. (PXLW) Crucell N.V. (CRXL) Crucell N.V. (CRXL) Crucell N.V. (CRXL)
Slam Exploration SXL TSX Venture Slam Exploration SXL TSX Venture Slam Exploration SXL TSX Venture SOXL 3xSemiu0027s SOXL 3xSemiu0027s SOXL 3xSemiu0027s
Excel Switching Corporation (XLSW) Excel Switching Corporation (XLSW) Excel Switching Corporation (XLSW) EXLN - Excelon EXLN - Excelon EXLN - Excelon
CUSIP: G98290102